University of Birmingham Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion
暂无分享,去创建一个
Sandra VanPelt Nguyen | M. Ezekowitz | J. Halperin | A. Breazna | J. Oldgren | N. Cater | C. Pollack | Judith Spahr | R. England | Maria Sudworth | P. Kirchhof | S. Nguyen | Sandra Nguyen
[1] G. Lip,et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial , 2016, The Lancet.
[2] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[3] P. Kirchhof,et al. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. , 2016, American heart journal.
[4] G. Lip,et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). , 2016, American heart journal.
[5] R. de Caterina,et al. Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48 , 2016, Clinical cardiology.
[6] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[7] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.
[8] A. Camm,et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.
[9] Jun Zhu,et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.
[10] Hugh Calkins,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.
[11] Theresa M. Beckie,et al. Council on Cardiovascular and Stroke Nursing. , 2014, The Journal of cardiovascular nursing.
[12] Mary G. George,et al. An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[13] G. Breithardt,et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.
[14] D. Singer,et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[15] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[16] S. Yusuf,et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.
[17] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[18] J. Mayet,et al. Anticoagulation for cardioversion of atrial fibrillation. , 2002, Minerva cardioangiologica.
[19] F. Loop,et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. , 1992, Journal of the American College of Cardiology.
[20] O. Orning,et al. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. , 1969, The American journal of cardiology.
[21] Rimm,et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.